Sentrimed

Sentrimed email format

Verified email-pattern data for Sentrimed is currently limited. You can still use the company insights and contact sections below.
Sentrimed is a clinical-stage biopharmaceutical company creating safer, orally dosed oncology therapies that target the cancer biomarker podoplanin (PDPN). PDPN is a transmembrane glycoprotein receptor that enables cancer cells to proliferate and migrate. This biomarker appears early in cancer transformation, persists through malignant progression, and causes poor clinical outcomes. As a result, targeting PDPN could represent an important advancement in the profiling and treatment of cancer. The Company’s lead product candidate, MASL, is an orally administered therapeutic that targets the PDPN receptor. MASL is a leader in a new drug class called oncolectins and represents a novel approach to addressing common challenges in oncology treatments, including drug resistance and highly immunosuppressive tumor microenvironments—which contribute to high recurrence rates and poor patient outcomes. Blocking PDPN by MASL inhibits cancer by altering pathways critical to tumor growth, invasion, evasion and resistance - specifically RAS-GTP, TGF-β SMAD, JAK-STAT, and WNT/β-catenin. Additionally, MASL triggers necrotic cell death, which causes host anti-tumor immune responses.

Company Details

Employees
6
Founded
-
Address
South Jersey Technology Park At Rowan University,
Industry
Biotechnology Research
Keywords
Cambridge.
HQ
Mullica Hill, NJ
Looking for a particular Sentrimed employee's phone or email?

Sentrimed Questions

Explore related pages

Related company profiles:

Top Sentrimed Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant